Event Date: September 21 – 22, 2022
Time: 11:00 am – 3:00 pm ET
This is a fascinating, exciting, and perplexing time for biotechnology. The industry delivered RNA vaccines to save countless lives during the pandemic and has created impressive early clinical results using CRISPR gene editing to treat patients with deadly genetic diseases. And yet the sector has been tarnished with safety concerns, drug failures, and lay-offs.
For more than 40 years, Genetic Engineering & Biotechnology News (GEN) has been covering the world of biotechnology. This September, we will cover it as never before – in a must-attend virtual event hosted by GEN Edge, the premium subscription news service of GEN.
THE STATE OF BIOTECH is an essential virtual summit (spanning two half days) featuring leaders from industry, academia, and finance discussing the latest critical breakthroughs, trends, and challenges in the biotech industry. The event will feature presentations and conversations with a trove of biotech leaders and entrepreneurs, brilliant scientists and innovators, and renowned analysts and commentators.
Among our guests will be:
- Jennifer Doudna (IGI/HHMI)
- Hana El-Samad (Altos Labs)
- John Evans (Beam Therapeutics)
- Andrew Hopkins (Exscientia)
- Peter Hotez (Baylor Coll Medicine)
- Daphne Koller (insitro)
- Bob Langer (MIT)
- Emily Leproust (Twist)
- David Mittelman (Othram)
- Fyodor Urnov (IGI)
In addition, we’ll feature more than two dozen invited corporate showcase presentations, in which chief executives of groundbreaking biotech companies share their progress and goals (available on demand). Guests include BiomX, Deepcell, Element Bio, Insilico Medicine, Lexeo Therapeutics, Metagenomi, Oxford Nanopore, Pairwise, Seqster, and Synthekine.
Join the Editors of GEN and an all-star line-up of speakers and presenters as we analyze the state of biotechnology circa 2022 – a celebration of innovation, emerging technologies, and clinical successes and an in-depth appraisal of the headwinds and challenges facing the industry.